OBJECTIVE: Vascular disease is associated with increased plasma asymmetric dimethylarginine (ADMA) and homocysteine, and both are increased in renal failure. In cystathionine beta-synthase deficiency (CBS) there is severe hyperhomocysteinaemia, precocious vascular disease, and endothelial dysfunction. We investigated whether ADMA levels are elevated in CBS patients with and without renal impairment, and whether lowering plasma homocysteine also lowers ADMA. METHODS: We measured plasma homocysteine, arginine, asymmetric and symmetric dimethylarginines, nitrate + nitrite, creatinine and cystatin C in 23 CBS-deficient patients and 24 age-matched controls. RESULTS: In the patients, nitrate + nitrite and the ratio L: -arginine/ADMA were markedly reduced (21.6 +/- 6.1 vs 57.7 +/- 7.5 micromol/L and 132.9 +/- 24.7 vs 181.9 +/- 56.1, respectively, p < 0.001 for both), reflecting endothelial dysfunction. Plasma ADMA for the group was moderately increased (0.55 +/- 0.08 vs 0.49 +/- 0.07 micromol/L, p = 0.018), but this was due to significantly higher levels than controls in only those 7 of the 23 patients who had elevated cystatin C levels (0.59 +/- 0.08 vs 0.49 +/- 0.07 mg/L, p = 0.007). Posttreatment total homocysteine in patients varied widely (15-285, median 92 micromol/L), but was not correlated with ADMA or other measured variables. In three newly-diagnosed patients, marked reduction of total homocysteine during treatment produced minimal changes in ADMA. CONCLUSIONS: ADMA levels were significantly increased only in the CBS-deficient patients with elevated cystatin C levels, and not in those with normal renal function. The reported relationship between hyperhomocysteinaemia and ADMA may not be direct, but could be secondary to reduced renal function.
OBJECTIVE:Vascular disease is associated with increased plasma asymmetric dimethylarginine (ADMA) and homocysteine, and both are increased in renal failure. In cystathionine beta-synthase deficiency (CBS) there is severe hyperhomocysteinaemia, precocious vascular disease, and endothelial dysfunction. We investigated whether ADMA levels are elevated in CBSpatients with and without renal impairment, and whether lowering plasma homocysteine also lowers ADMA. METHODS: We measured plasma homocysteine, arginine, asymmetric and symmetric dimethylarginines, nitrate + nitrite, creatinine and cystatin C in 23 CBS-deficientpatients and 24 age-matched controls. RESULTS: In the patients, nitrate + nitrite and the ratio L: -arginine/ADMA were markedly reduced (21.6 +/- 6.1 vs 57.7 +/- 7.5 micromol/L and 132.9 +/- 24.7 vs 181.9 +/- 56.1, respectively, p < 0.001 for both), reflecting endothelial dysfunction. Plasma ADMA for the group was moderately increased (0.55 +/- 0.08 vs 0.49 +/- 0.07 micromol/L, p = 0.018), but this was due to significantly higher levels than controls in only those 7 of the 23 patients who had elevated cystatin C levels (0.59 +/- 0.08 vs 0.49 +/- 0.07 mg/L, p = 0.007). Posttreatment total homocysteine in patients varied widely (15-285, median 92 micromol/L), but was not correlated with ADMA or other measured variables. In three newly-diagnosed patients, marked reduction of total homocysteine during treatment produced minimal changes in ADMA. CONCLUSIONS:ADMA levels were significantly increased only in the CBS-deficientpatients with elevated cystatin C levels, and not in those with normal renal function. The reported relationship between hyperhomocysteinaemia and ADMA may not be direct, but could be secondary to reduced renal function.
Authors: S Yap; G H Boers; B Wilcken; D E Wilcken; D P Brenton; P J Lee; J H Walter; P M Howard; E R Naughten Journal: Arterioscler Thromb Vasc Biol Date: 2001-12 Impact factor: 8.311
Authors: C Zoccali; S Bode-Böger; F Mallamaci; F Benedetto; G Tripepi; L Malatino; A Cataliotti; I Bellanuova; I Fermo; J Frölich; R Böger Journal: Lancet Date: 2001 Dec 22-29 Impact factor: 79.321
Authors: Markus C Stühlinger; Roberta K Oka; Eric E Graf; Isabella Schmölzer; Barbara M Upson; Om Kapoor; Andrzej Szuba; M Rene Malinow; Thomas C Wascher; Otmar Pachinger; John P Cooke Journal: Circulation Date: 2003-08-11 Impact factor: 29.690
Authors: S H Mudd; F Skovby; H L Levy; K D Pettigrew; B Wilcken; R E Pyeritz; G Andria; G H Boers; I L Bromberg; R Cerone Journal: Am J Hum Genet Date: 1985-01 Impact factor: 11.025
Authors: M Barroso; M S Rocha; R Esse; I Gonçalves; A Q Gomes; T Teerlink; C Jakobs; H J Blom; J Loscalzo; I Rivera; I Tavares de Almeida; R Castro Journal: Amino Acids Date: 2011-05-26 Impact factor: 3.520
Authors: Sanjana Dayal; Roman N Rodionov; Erland Arning; Teodoro Bottiglieri; Masumi Kimoto; Daryl J Murry; John P Cooke; Frank M Faraci; Steven R Lentz Journal: Am J Physiol Heart Circ Physiol Date: 2008-06-20 Impact factor: 4.733
Authors: Sally P Stabler; Mark Korson; Reena Jethva; Robert H Allen; Jan P Kraus; Elaine B Spector; Conrad Wagner; S Harvey Mudd Journal: JIMD Rep Date: 2013-06-04